The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from CNW Group

Allon director takes new role

Wednesday, January 30, 2013

Allon director takes new role17:30 EST Wednesday, January 30, 2013VANCOUVER, Jan. 30, 2013 /CNW/ - Allon Therapeutics Inc. (TSX: NPC) announced today that Mr. Michael Aldridge, Director of the Company since June 2011, has resigned to accept a new professional responsibility in the biotech industry."We are grateful for Michael's involvement and expertise, which contributed to Allon's achievements over the last few years," said Gordon McCauley, President and CEO.About AllonAllon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC".Forward Looking StatementsStatements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.SOURCE: Allon Therapeutics Inc.For further information: Carrie Christenson 604-736-0634 info@allontherapeutics.com www.allontherapeutics.com